Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2016

Open Access 01-12-2016 | Research

Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens

Authors: Soodabeh Iranpour, Vahid Nejati, Nowruz Delirezh, Pouria Biparva, Sadegh Shirian

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2016

Login to get access

Abstract

Background

Developing safe and effective cancer vaccine formulations is a primary focus in the field of cancer immunotherapy. Dendritic cells (DC) are currently employed as cellular vaccine in clinical trials of tumor immunotherapy. Recognizing the critical role of DCs in initiating anti-tumor immunity has resulted in the development of several strategies that target vaccine antigens to DCs to trigger anti-tumor T cell responses. To increase the efficiency of antigen delivery systems for anti-tumor vaccines, encapsulation of tumor-associated antigens in polymer nanoparticles (NPs) has been established.

Methods

In this study, the effect of tumor lysate antigen obtained from three stage III breast cancer tissues encapsulated within PLGA NPs to enhance the DC maturation was investigated. The T-cell immune response activation was then fallowed up. Fresh breast tumors were initially used to generate tumor lysate antigens containing poly lactic-co-glycolic acid (PLGA) NP. The encapsulation efficiency and release kinetics were profiled. The efficiency of encapsulation was measured using Bradford protein assays measuring the dissolved NPs. The stability of released antigen from NPs was verified using SDS-PAGE. To evaluate the hypothesis that NPs enhances antigen presentation, including soluble tumor lysate, tumor lysate containing NPs and control NPs the efficiency of NP-mediated tumor lysate delivery to DCs was evaluated by assessing CD3+ T-cell stimulation after T cell/and DCs co-culture.

Results

The rate of encapsulation was increased by enhancing the antigen concentration of tumor lysate. However, increasing the antigen concentration diminished the encapsulation efficiency. In addition, higher initial protein contenting NPs led to a greater cumulative release. All three patients released variable amounts of IFN-γ, IL-10, IL-12 and IL-4 in response to re-stimulation. T cells stimulated with lysate-pulsed DCs induced a substantial increase in IFN-γ and IL-12 production. We demonstrated that NPs containing tumor lysate can induce maturation and activation of DCs, as antigen alone does.

Conclusion

PLGA-NPs are attractive vehicles for protein antigen delivery which effectively induce stimulation and maturation of DCs, allowing not only an enhanced antigen processing and immunogenicity or improved antigen stability, but also the targeted delivery and slow release of antigens.
Literature
1.
go back to reference Zhou J, Zhong Y. Breast cancer immunotherapy. Cell Mol Immunol. 2004;1(4):247–55.PubMed Zhou J, Zhong Y. Breast cancer immunotherapy. Cell Mol Immunol. 2004;1(4):247–55.PubMed
2.
go back to reference Heiser A, Coleman D, Dannull J, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulates CTL responses against metastatic prostatetumors. J Clin Investig. 2002;109(3):409–17.CrossRefPubMedPubMedCentral Heiser A, Coleman D, Dannull J, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulates CTL responses against metastatic prostatetumors. J Clin Investig. 2002;109(3):409–17.CrossRefPubMedPubMedCentral
3.
go back to reference Fournier P, Schirrmacher V. Randomized clinical studies of anti-tumorvaccination: state of the art in 2008. Expert Rev Vaccines. 2009;8:51–66.CrossRefPubMed Fournier P, Schirrmacher V. Randomized clinical studies of anti-tumorvaccination: state of the art in 2008. Expert Rev Vaccines. 2009;8:51–66.CrossRefPubMed
4.
go back to reference Georgiannos SN, Renaut A, Goode AW, et al. The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators. Surgery. 2003;134:827–34.CrossRefPubMed Georgiannos SN, Renaut A, Goode AW, et al. The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators. Surgery. 2003;134:827–34.CrossRefPubMed
5.
go back to reference Reome JB, Hylind JC, Dutton RW, et al. Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer. Clin Immunol. 2004;111:69–81.CrossRefPubMed Reome JB, Hylind JC, Dutton RW, et al. Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer. Clin Immunol. 2004;111:69–81.CrossRefPubMed
6.
go back to reference Sabel MS, Skitzki J, Stoolman L, et al. Intratumoral IL-12 and TNF-α-loaded microspheres lead to regression of breast cancer and systemic anti-tumor immunity. Ann Surg Oncol. 2004;11:147–56.CrossRefPubMed Sabel MS, Skitzki J, Stoolman L, et al. Intratumoral IL-12 and TNF-α-loaded microspheres lead to regression of breast cancer and systemic anti-tumor immunity. Ann Surg Oncol. 2004;11:147–56.CrossRefPubMed
7.
go back to reference Mocellin S, Mandruzzato S, Bronte V, et al. Part I: vaccines for solid tumurs. Lancet Oncol. 2004;5:681–9.CrossRefPubMed Mocellin S, Mandruzzato S, Bronte V, et al. Part I: vaccines for solid tumurs. Lancet Oncol. 2004;5:681–9.CrossRefPubMed
8.
go back to reference Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol. 2005;23:975.CrossRefPubMed Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol. 2005;23:975.CrossRefPubMed
10.
go back to reference Adams S, O’Naill DW, Bhardwaj N. Recent advances in dendritic cell biology. J Clin Immunol. 2005;25(2):87–98.CrossRefPubMed Adams S, O’Naill DW, Bhardwaj N. Recent advances in dendritic cell biology. J Clin Immunol. 2005;25(2):87–98.CrossRefPubMed
11.
go back to reference Delirezh N, Moazzeni SM, Shokri F, et al. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro. Cell Immunol. 2009;257:23–31.CrossRefPubMed Delirezh N, Moazzeni SM, Shokri F, et al. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro. Cell Immunol. 2009;257:23–31.CrossRefPubMed
12.
go back to reference Hamdy S, Haddadi A, Hung RW, et al. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev. 2011;63:943–55.CrossRefPubMed Hamdy S, Haddadi A, Hung RW, et al. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev. 2011;63:943–55.CrossRefPubMed
14.
go back to reference Gamvrellis A, Leong D, Hanley JC, et al. Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell Biol. 2004;82:506.CrossRefPubMed Gamvrellis A, Leong D, Hanley JC, et al. Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell Biol. 2004;82:506.CrossRefPubMed
16.
go back to reference Salvador A, Sandgren KJ, Liang F, et al. Design and evaluation of surface and adjuvant modified PLGAmicrospheres for uptake by dendritic cells to improve vaccineresponses. Int J Pharm. 2015;496(2):371–81.CrossRefPubMed Salvador A, Sandgren KJ, Liang F, et al. Design and evaluation of surface and adjuvant modified PLGAmicrospheres for uptake by dendritic cells to improve vaccineresponses. Int J Pharm. 2015;496(2):371–81.CrossRefPubMed
17.
go back to reference Johansen P, Men Y, Merkle HP, et al. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm. 2000;50:129.CrossRefPubMed Johansen P, Men Y, Merkle HP, et al. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm. 2000;50:129.CrossRefPubMed
18.
go back to reference Jiang W, Gupta RK, Deshpande MC, et al. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev. 2005;57:391–410.CrossRefPubMed Jiang W, Gupta RK, Deshpande MC, et al. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev. 2005;57:391–410.CrossRefPubMed
19.
go back to reference Bradford MM. A rapid and sensitive for the quantization of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.CrossRefPubMed Bradford MM. A rapid and sensitive for the quantization of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.CrossRefPubMed
20.
go back to reference Solbrig CM, Saucier-Sawyer JK, Cody V, et al. Polymer nanoparticles for immunotherapy from encapsulated tumor associated antigens and whole tumor cells. Mol Pharm. 2007;4:47–57.CrossRefPubMed Solbrig CM, Saucier-Sawyer JK, Cody V, et al. Polymer nanoparticles for immunotherapy from encapsulated tumor associated antigens and whole tumor cells. Mol Pharm. 2007;4:47–57.CrossRefPubMed
21.
go back to reference Prasad SH, Cody V, Saucier-Sawyer JK, et al. Polymer nanoparticles containing tumor lysates as antigen deliveryvehicles for dendritic cell–based antitumor immunotherapy. Nanomedicine. 2011;7:1–10.PubMed Prasad SH, Cody V, Saucier-Sawyer JK, et al. Polymer nanoparticles containing tumor lysates as antigen deliveryvehicles for dendritic cell–based antitumor immunotherapy. Nanomedicine. 2011;7:1–10.PubMed
22.
go back to reference Wong HM, Wang JJ, Wang CH. In vitro sustained release of human immunoglobulin G from biodegradable microspheres. Ind Eng Chem Res. 2001;40:933–48.CrossRef Wong HM, Wang JJ, Wang CH. In vitro sustained release of human immunoglobulin G from biodegradable microspheres. Ind Eng Chem Res. 2001;40:933–48.CrossRef
23.
go back to reference Sandor M, Enscore D, Weston P, et al. Effect of protein molecular weight on release from micron-sized PLGA microspheres. J Control Release. 2001;76:297–311.CrossRefPubMed Sandor M, Enscore D, Weston P, et al. Effect of protein molecular weight on release from micron-sized PLGA microspheres. J Control Release. 2001;76:297–311.CrossRefPubMed
24.
go back to reference Hans ML, Lowman AM. Biodegradable nanoparticles for drug deliveryand targeting. Curr Opinion Solid State Mater Sci. 2002;6:319–27.CrossRef Hans ML, Lowman AM. Biodegradable nanoparticles for drug deliveryand targeting. Curr Opinion Solid State Mater Sci. 2002;6:319–27.CrossRef
25.
go back to reference Audran R, Peter K, Dannull J, et al. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine. 2003;21:1250–5.CrossRefPubMed Audran R, Peter K, Dannull J, et al. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine. 2003;21:1250–5.CrossRefPubMed
26.
go back to reference Silva AL, Rosalia RA, Sazak A, et al. Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: low-burst release is crucial for efficient CD8(+) T cell activation. Eur J Pharm Biopharm. 2013;83:338–45.CrossRefPubMed Silva AL, Rosalia RA, Sazak A, et al. Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: low-burst release is crucial for efficient CD8(+) T cell activation. Eur J Pharm Biopharm. 2013;83:338–45.CrossRefPubMed
27.
go back to reference Mac Keon S, Sol Ruiz M, Gazzaniga S, et al. Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models. Front Immunol. 2015;6:243.CrossRefPubMedPubMedCentral Mac Keon S, Sol Ruiz M, Gazzaniga S, et al. Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models. Front Immunol. 2015;6:243.CrossRefPubMedPubMedCentral
28.
go back to reference Klippstein R, Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine. 2010;6(4):523–9.PubMed Klippstein R, Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine. 2010;6(4):523–9.PubMed
29.
go back to reference Vassallo R, Tamada K, Lau JS, et al. Cigarette smoke extract suppresses human dendritic cell function leading to preferential induction of Th-2 priming. J Immunol. 2005;175:2684–91.CrossRefPubMed Vassallo R, Tamada K, Lau JS, et al. Cigarette smoke extract suppresses human dendritic cell function leading to preferential induction of Th-2 priming. J Immunol. 2005;175:2684–91.CrossRefPubMed
Metadata
Title
Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens
Authors
Soodabeh Iranpour
Vahid Nejati
Nowruz Delirezh
Pouria Biparva
Sadegh Shirian
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2016
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-016-0444-6

Other articles of this Issue 1/2016

Journal of Experimental & Clinical Cancer Research 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine